Tafamidis meglumine

(Vyndaqel®)

Tafamidis meglumine

Drug updated on 11/14/2023

Dosage FormCapsule (oral: 20 mg)
Drug ClassTransthyretin stabilizers
Ongoing and
Completed Studies
ClinicalTrials.gov

Indication

  • For the treatment of the cardiomyopathy of wild type or hereditary transthyretin-mediated amyloidosis in adults to reduce cardiovascular mortality and cardiovascular-related hospitalization.